Ancillary Study to Protocol 20060104

Ancillary study to the Etanercept protocol 20060104. Subjects have been asked to provide additional blood samples for further assessment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rheumatoid Arthritis Arthritis Arthritis, Rheumatoid Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Signed informed Consent Meet all inclusion critieria outlined in Amgen Protocol 20060104

Exclusion criteria

Meet exclusion criteria outlined in Amgen Protocol 20060104

Treatment and study plan

Blood draw

Procedure

blood draw at baseline, week 12 and week 24

Primary outcomes

To explore the correlation between pheripheral blood cell protein phosphorylation assessemnts and rheumatoid arthritis disease activity.

Time frame: week 24

Secondary outcomes

Explore the correlations to etanercept clinical response (ACR and DAS scores) may also be explored.

Time frame: week 24

Sponsors and collaborators

Lead sponsor

Amgen

Industry

Registry information

Official study title

Protein Phosphorylation Ancillary Study to Amgen Protocol 20060104: Open Label Study to Assess the Safety and Immunogenicity of Etanercept SFP When Administered to Subjects Diagnosed With Rheumatoid Arthritis

Important dates

Study start: 2006
Primary completion: 2007
Study completion: 2007
First posted: Feb 26, 2007
Registry last updated: Mar 21, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed